Physician profile
David Borg
NPI 1639527898
$1,599.26
in general payments reported to CMS, 2019-2025
22 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.48 · 2022: $139 · 2024: $295 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $318.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $295.75 | 2024-2025 | Airsupra, Bevespi Aerosphere, Farxiga |
| Amgen INC. | $209.17 | 2024-2025 | Evenity, Otezla, Repatha |
| Baxter Healthcare | $117.79 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $84.67 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $83.61 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $69.55 | 2024-2025 | |
| Astellas Pharma US INC | $59.50 | 2024-2025 | Veozah |
| Welch Allyn | $50.48 | 2021 | |
| Lilly USA, LLC | $41.21 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $41.12 | 2025 | Ozempic |
| Lundbeck LLC | $35.99 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.12 | 2025 | Trintellix |
| Sanofi Pasteur INC. | $24.35 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.67 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.37 | 2022 | |
| Glaxosmithkline, LLC. | $19.62 | 2024 | Shingrix, Bexsero, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.78 | 2025 | Caplyta |
| Ardelyx, INC. | $16.68 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.33 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $15.20 | 2025 | |
| Corcept Therapeutics | $14.44 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Borg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.